19 results on '"Schmitz, Manuela"'
Search Results
2. Additional file 8 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
3. Additional file 5 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
4. Additional file 1 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
5. Additional file 2 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
6. Additional file 7 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
7. Additional file 4 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
8. Additional file 9 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
9. Additional file 6 of Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
10. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin
11. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions
12. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials
13. Baseline predictors of null-response to peginterferon (PegIFN) α2a (40KD)/ribavirin (RBV) in treatment-naive patients with chronic hepatitis C (CHC) infected with HCV genotype 1: analysis of data from the multinational PROPHESYS cohorts: 811
14. Impact of baseline (BL) HCV RNA to predict treatment outcome in HCV genotype 2 and 3 patients receiving peginterferon (PegIFN) alfa-2a (40KD)/ribavirin (RBV): analysis of data from the multinational PROPHESYS cohorts: 787
15. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
16. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHeSYS study
17. In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions
18. Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
19. SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.